compound introduction
AG-636 是一种选择性可逆和具有口服活性的二氢乳清酸脱氢酶(DHODH)抑制剂，IC50 为 17 nM，具有很强的抗癌作用。 Information AG-636 AG-636 is an orally available inhibitor of dihydroorotate dehydrogenase (DHODH) with potential antineoplastic activity. Targets DHODH In vitro AG-636 reveals a strong enrichment in sensitivity to a novel dihydroorotate dehydrogenase (DHODH) in cancer cell lines of hematologic versus solid tumor origin. In vivo AG-636 results in robust tumor growth inhibition in xenograft lymphoma tumor models, with comparably poor activity in solid tumor models. Cell Research(from reference) Cell lines：Z138 cells, OCILY19 cells, JEKO1 cells, HCT116 cells, A549 cells Concentrations：10 μM Incubation Time：96 h
